Beranda › Kanker Kandung Kemih Non-Invasif Otot › Ohio
Uji klinis Kanker Kandung Kemih Non-Invasif Otot di Ohio
13 studi untuk Kanker Kandung Kemih Non-Invasif Otot mencari peserta di lokasi di Ohio.
Kota di Ohio
Teks studi resmi (Bahasa Inggris)
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- Ohio State University Comprehensive Cancer Center, Columbus
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07000084A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122), Cincinnati
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06833073Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- The James at Brain and Spine Hospital (OSU), Columbus
- Oregon Urology Institute, Springfield
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06995677A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Dayton Physicians Network Urology, Centerville
- Central Ohio Urology Group, Gahanna
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06919965Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
- University Hospitals Cleveland Medical Center, Cleveland
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05796375Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Cleveland Clinic Main Campus, Cleveland, Cleveland
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05951179FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Cincinnati Medical Center (UCMC), Cincinnati
- The Ohio State University (OSU), Columbus
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT05614739LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- University of Cincinnati Medical Center, Cincinnati
- Central Ohio Urology Group, Gahanna
- Clinical Research Solutions - Helios Clinical Research, Middleburg Heights
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- The Ohio State University, Columbus
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT07225127A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
- The Ohio State University, Columbus
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT05710848Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Mar 2026 · NCT07474519Blue Light Cystoscopy With Cysview® Registry
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Des 2025 · NCT02660645Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
- Site 02-017 - Central Ohio Urology Group, Gahanna
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Nov 2025 · NCT03945162Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.